Exact Sciences Corp (EXAS) USD0.01

Sell:$55.25Buy:$56.50$1.14 (2.08%)

Prices delayed by at least 15 minutes
Sell:$55.25
Buy:$56.50
Change:$1.14 (2.08%)
Prices delayed by at least 15 minutes
Sell:$55.25
Buy:$56.50
Change:$1.14 (2.08%)
Prices delayed by at least 15 minutes

Company Information

About this company

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Key people

Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Aaron Bloomer
Chief Financial Officer
Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Jacob Orville
Executive Vice President, General Manager - Screening
Sarah Condella
Executive Vice President - Human Resources
Everett V. Cunningham
Executive Vice President
James Michael Jo Herriott
Senior Vice President, General Counsel, Company Secretary
James E. Doyle
Lead Independent Director
D. Scott Coward
Director
Kimberly J. Popovits
Director
Paul Clancy
Independent Director
Daniel J. Levangie
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US30063P1057
  • Market cap
    $10.26bn
  • Employees
    6,500
  • Shares in issue
    185.08m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.